Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

ClinicalTrials.gov ID: NCT06964464

Public ClinicalTrials.gov record NCT06964464. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This prospective, multicenter, open-label, randomized comparative effectiveness trial, titled CARVTOP-ICD, evaluates the impact of carvedilol versus metoprolol succinate in patients with heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD). The study will enroll 2,000 participants across 100 U.S. sites and includes an 18-month feasibility phase with 100 participants from 15 sites. Eligible participants must be currently treated with metoprolol succinate and willing to switch to carvedilol, with randomization in a 1:1 ratio. Participants will be followed for up to 3 years, with regular assessments including ICD interrogations, medication adherence, healthcare utilization, and quality of life surveys. The primary endpoint is the first occurrence of any ICD therapy (appropriate or inappropriate), cardiovascular (CV) hospitalization, or CV death. Secondary endpoints include ICD shock burden, healthcare utilization, and patient-reported quality of life. The trial aims to provide high-quality comparative data to address clinical equipoise surrounding the two commonly used beta-blockers in HFrEF management.

Study identification

NCT ID: NCT06964464
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: University of Rochester; Other
Enrollment: 2,000 participants

Conditions and interventions

Conditions

Interventions

Metoprolol Succinate Drug
Carvedilol Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 16, 2025
Primary completion: May 31, 2031
Completion: Jun 30, 2031
Last update posted: Sep 17, 2025

2025 – 2031

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
HonorHealth	Scottsdale	Arizona	85258	Recruiting
AdventHealth Redmond	Rome	Georgia	30165	Recruiting
AdventHealth Shawnee Mission	Shawnee Mission	Kansas	66204	Recruiting
Henry Ford Health System	Detroit	Michigan	48202	Recruiting
University of Mossouri	Columbia	Missouri	65212	Recruiting
Creighton University Medical Center	Omaha	Nebraska	68124	Recruiting
Suny Downstate	Brooklyn	New York	11203	Recruiting
New York-Presbyterian Brooklyn Methodist Hospital	Brooklyn	New York	11215	Recruiting
University of Rochester Medical Center	Rochester	New York	14642	Recruiting
CHRISTUS Trinity Mother Frances Health System	Tyler	Texas	75701	Recruiting
Health University of Utah	Salt Lake City	Utah	84112	Recruiting
Virginia Commonwealth University	Richmond	Virginia	23298	Recruiting
University of Wisconsin Hospital and Clinics	Madison	Wisconsin	53792	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06964464, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 17, 2025 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06964464 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →